STERIS Life Sciences: — Revenue increased by 0.6% to $145.80M in Q4 2025 compared to the prior quarter. This is a positive signal — higher values indicate stronger performance for this metric.
An increase indicates growing market share or higher demand for biopharma manufacturing solutions, while a decrease may signal market saturation or reduced capital spending by pharmaceutical clients.
This metric represents the total revenue generated from the Life Sciences business segment, which provides sterilization...
Comparable to segment-level revenue reporting in other medical technology or life science tools companies.
ste_segment_life_sciences_revenues| Q3 '24 | Q4 '24 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|
| Value | $127.90M | $136.40M | $145.00M | $145.80M |
| QoQ Change | — | +6.6% | +6.3% | +0.6% |
| YoY Change | — | — | +13.4% | +6.9% |